Table 2 Comparison of patients with and without renal atrophy 24Â months after the start of glucocorticoid therapy
|  | Atrophy (+) (n = 11) | Atrophy (-) (n = 12) | P value |
|---|---|---|---|
Age (years) | 62.6 ± 10.7 | 61.6 ± 13.5 | 0.951 |
Gender (male, %) | 72.7 | 75.0 | 1.000 |
Allergy (%) | 54.5 | 75.0 | 0.400 |
Number of extra-renal organs | 2.8 ± 1.0 | 3.3 ± 1.6 | 0.423 |
IgG4 (mg/dL) | 909 ± 587 | 1216 ± 454 | 0.065 |
IgG (mg/dL) | 3001 ± 1505 | 3040 ± 1015 | 0.424 |
IgE (IU/mL) | 587 ± 254 | 284 ± 263 | 0.008 |
CH50 (IU/L) | 31.0 ± 20.5 | 34.9 ± 14.8 | 0.498 |
CRP (mg/dL) | 0.31 ± 0.38 | 0.19 ± 0.32 | 0.251 |
Cr (mg/dL) | 1.23 ± 0.59 | 0.80 ± 0.20 | 0.052 |
eGFR (mL/min/1.73 m2) | 68.9 ± 30.1 | 93.5 ± 14.1 | 0.036 |
Initial dose of PSL (mg/kg/day) | 0.52 ± 0.18 | 0.62 ± 0.16 | 0.124 |
Other immunosuppressant drugs (%) | 9.1 | 33.3 | 0.317 |
ARB (%) | 27.3 | 16.7 | 0.640 |
Relapse (%) | 18.2 | 50.0 | 0.193 |
Diabetes mellitus (%) | 36.4 | 25.0 | 0.667 |
Hypertension (%) | 27.3 | 16.7 | 0.640 |
Ischemic heart disease (%) | 0 | 8.3 | 1.000 |
Smoking habit (%) | 50.0 | 54.5 | 1.000 |